![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 41, 38863-38869, October 11, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
§,
,
,
,
,
,
,
, and
From the
Third Department of Medicine and
¶ Department of Anatomy, Shiga University of Medical Science,
Seta, Otsu, Shiga 520-2192, Japan
Received for publication, April 2, 2002, and in revised form, July 8, 2002
| |
ABSTRACT |
|---|
|
|
|---|
It is reported that
3-phosphoinositide-dependent protein kinase-1 (PDK-1) is
activated in a phosphatidylinositol
3,4,5-trisphosphate-dependent manner and phosphorylates
Akt, p70S6 kinase, and atypical protein kinase C (PKC), but its
function on insulin signaling is still unclear. We cloned a full-length
pdk-1 cDNA from a human brain cDNA library, and the
adenovirus to overexpress wild type PDK-1 (PDK-1WT) or
membrane-targeted PDK-1 (PDK-1CAAX) was constructed. Overexpressed
PDK-1WT existed mainly at cytosol, and PDK-1CAAX was located at the
plasma membrane. In 3T3-L1 adipocytes, insulin induced mobility shift
of PDK-1 protein, but overexpressed PDK-1WT and CAAX were shifted at
the basal state. Insulin stimulated tyrosine phosphorylation of
PDK-1WT, but PDK-1CAAX was already tyrosine-phosphorylated at the basal
state. Overexpression of PDK-1WT led to a full activation of PKC One of the major effects of insulin is stimulation of glucose
transport with translocation of glucose transporter 4 Glut4.1 The overexpression of
either the N-terminal Src homology 2 domain of the p85 subunit
of phosphatidylinositol (PI) 3-kinase or Akt and atypical protein kinase C (PKC), such as PKC Recently, 3-phosphoinositide-dependent protein kinase-1
(PDK-1) was cloned from rabbit skeletal muscle extracts (7) or sheep
brain cytosol (8) as a protein kinase that phosphorylated Akt at
Thr308 and increased its activity in the presence of
phosphatidylinositol 3,4,5-trisphosphate. p70S6 kinase, which is
another downstream molecule of PI 3-kinase, is also phosphorylated at
Thr252 and Thr412 by PDK-1 in vivo
and in vitro (9-11). Moreover, PDK-1 directly phosphorylates the activation loop of PKC In this study, we overexpressed wild type and membrane targeted PDK-1
in 3T3-L1 adipocytes by adenovirus-mediated gene transfer and examined
the role of PDK-1 on insulin signaling. Overexpression of wild type
PDK-1 stimulated atypical PKC activity but small effects for Akt
phosphorylation. On the other hand, a membrane-targeted PDK-1 enhanced
the phosphorylation of Akt and GSK-3 at the basal condition but
inhibited glycogen synthesis and insulin-stimulated ERK
phosphorylation. Moreover, neither wild type nor
membrane-targeted PDK-1 enhances glucose transport in 3T3-L1
adipocytes. This finding suggests that PDK-1 stimulates atypical PKC
and Akt by different mechanisms, and localization of PDK-1 is important
for regulation of downstream signaling but another mechanism is still
needed for total activation.
Materials--
Human insulin was provided by Eli Lilly,
Inc. (Indianapolis, IL). Anti-PDK-1 antibody was purchased from
Upstate Biotechnology Incorporated (Lake Placid, NY).
Anti-phosphospecific-PKC Isolation of the pdk-1 cDNA--
The partial nucleotide
sequence containing complete open reading frame of human
pdk-1 cDNA (GenBankTM accession number
AF017995) was amplified from total RNA of HepG2 cells by reverse
transcription-PCR reaction with use of the primers
5'-gcccatggccaggaccaccagc-3' and 5'-tcactgcacaagcgcgtccg-3', and the
fragments were subcloned into pCR2.1 vector (Invitrogen). The 1.6-kb
fragments obtained were used as a probe for standard plaque
hybridization with a human brain cDNA library (Catalog no. 937223, Stratagene, La Jolla, CA). After purification of
After confirmation of the sequence, a FLAG epitope (MDYLDDDDK) was
added by an another PCR reaction using the following primers 5'-catggactacaaggacgacgatgacaaggcccatggccaggaccaccag-3' and
5'-tcactgcacagcggcgtccg-3', and the fragment (pdk-1 residues
2-556 with the N-terminal FLAG tag) was subcloned into pCR2.1
(17).
Baculovirus Constructs--
Subcloned cDNA of
FLAG-pdk-1 in pCR2.1 was digested with EcoRI and
subcloned into baculovirus transfer vector pVL1393 (PharMingen, San
Diego, CA). His-tagged mouse akt-1 (His-Akt), which was
subcloned in a mammalian expression vector (pCMV6) and provided by Dr.
A. Bellacosa, was also subcloned into pVL1393 with EcoRI
site. These plasmids were co-transfected with Baculo-Gold linearized
DNA into Sf-9 cells according to the manufacturer's instruction (PharMingen).
Effect of Co-expression of PDK-1 on Akt Phosphorylation in Sf-9
Cells--
Recombinant His-tagged Akt-1 baculovirus was infected to
Sf-9 cells with or without following baculovirus including His-PDK-1 at
the indicated multiplicities of infection. After 60 h of
infection, cells were washed with ice-cold PBS and lysed in a
solubilizing buffer containing 50 mM Tris-HCl (pH 7.5), 1 mM EGTA, 140 mM NaCl, 1% Nonidet P-40, 50 mM NaF, 50 mM Preparation of Recombinant Adenovirus--
PDK-1 wild type
adenovirus (Ad5-PDK-1WT) was provided by Dr. L. C. Cantley
(Harvard University, Boston, MA). The recombinant adenovirus containing
the cDNA encoding the membrane-targeted pdk-1,
PDK-1CAAX, was isolated by AdEasy system as described previously (18).
The recombinant plasmids, AdTrack-PDK-1CAAX and AdEasy, were purified
and co-transformed into Escherichia coli by
electroporation method. The recombinant plasmid,
AdEasy-PDK-1CAAX, was transfected into 293 cells. Because 293 cells
were originally derived from adenovirus transformation, the missing
E1 gene function of AdEasy is provided in
trans. The resulting recombinant virus containing the PDK-1CAAX is
denoted as Ad5-PDK-1CAAX and is replication-defective (at least in
cells lacking the E1 region of adenovirus) but fully infectious.
Cell Culture--
3T3-L1 preadipocytes, which were provided by
Dr. J. M. Olefsky, were grown and maintained in DME high glucose
medium (Invitrogen) containing 50 units/ml penicillin, 50 µg/ml
streptomycin, and 10% FCS in a 10% CO2 environment. The
cells were allowed to grow until 2 days postconfluency and then
differentiated by the addition of the same medium containing
isobutylmethylxanthine (500 µM), dexamethasone (25 µM), and insulin (4 µg/ml) for 3 days and the medium
containing insulin for 3 additional days. The medium was then changed
every 3 days until the cells were fully differentiated, typically after
15 days. Prior to experimentation, the adipocytes were trypsinized and
reseeded in the appropriate culture dishes.
Rat primary cultured hepatocytes were isolated from non-fasting 200-g
male Sprague-Dawley rats by the collagenase method described previously
(19). Animals were anesthetized, and the liver was perfused in
situ via the portal vein with 25 ml/min Krebs-Ringer phosphate
buffer. The liver was then perfused with Krebs-Ringer phosphate
buffer containing collagenase (Sigma) for 10 min at the same flow rate.
The dissociated cells were dispersed by shaking followed by filtration
at 4 °C through gauze into an equal volume of ice-cold DME medium
containing 10% FCS, 100 units/ml penicillin, and 100 mg/ml
streptomycin. The cells were precipitated and washed twice at 4 °C
with the same medium. The cell suspension (8 × 106) was plated onto 100-mm rat collagen I-coated dishes
(Asahi Techno Glass Co., Chiba, Japan) in William's E
Medium (Sigma) supplemented with 10% FCS, 6 ng/ml insulin,
100 nM triiodothyronine, 100 nM dexamethasone,
100 units/ml penicillin, and 100 mg/ml streptomycin. After incubation
at 37 °C in 9% CO2 for 3 h, the cells were washed twice with PBS and incubated with DME medium supplemented with 6 ng/ml
insulin, 100 nM triiodothyronine, 100 nM
dexamethasone, 100 units/ml penicillin, and 100 mg/ml streptomycin. The
Ad-E1A-transformed human embryonic kidney cell line 293 was cultured in
DME high glucose medium containing 50 units/ml penicillin, 50 µg/ml
streptomycin, and 10% FCS in a 5% CO2 environment.
Cell Treatment--
3T3-L1 adipocytes were infected at a
multiplicity of infection of 10-40 plaque-forming units/cell for
16 h with stocks of either a control recombinant adenovirus,
Ad5-ctrl, containing the cytomegalovirus promoter, pUC 18 polylinker,
and a fragment of the SV40 genome, the recombinant adenovirus Ad5-PDK-1
or Ad5-PDK-1CAAX. Transduced cells were incubated for
56 h at 37 °C in 10% CO2 and DME medium with 2%
heat inactivated serum followed by incubation in the starvation
medium required for the assay. Rat primary cultured hepatocytes
were infected at 10 m.o.i. of Ad5-PDK-1WT or Ad5-PDK-1CAAX for
1 h and incubated for 24 h at 37 °C in 10%
CO2. The efficiency of the adenovirus-mediated gene
transfer was ~90% as measured by immunocytochemistry. The survival
of the cells was unaffected by the incubation of cells with the
different adenovirus constructs, because the total cell protein
remained the same in infected or uninfected cells.
Immunohistochemical Analysis--
The cells were stained as
described previously (20). The cells were fixed for 2 h with 4%
paraformaldehyde and washed for 4 days with 0.1 M PBS
containing 0.3% Triton-X followed by incubation with an antibody
against PDK-1 diluted to 1:5000 in PBS containing 0.3% Triton-X. The
cells were then incubated with the species-specific secondary
antibodies conjugated to Texas Red. The positive reaction was observed
under fluorescence microscopy (Olympus IX70, Olympus Optical Co.,
Tokyo, Ltd., Japan), and the images were taken with CCD camera
(Cool SNAP/HQ, Nippon Roper Co., Chiba, Japan).
Western Blotting--
Ad5-ctrl-, Ad5-PDK-1WT, or
Ad5-PDK-1CAAX-infected cells were starved for 16 h in DME regular
glucose medium with 0.05% FCS. The cells were stimulated with
the indicated concentration of insulin for 5-30 min at 37 °C and
lysed in a solubilizing buffer containing 20 mM Tris, 1 mM EDTA, 140 mM NaCl, 1% Nonidet P-40, 50 units/ml aprotinin, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, and 50 mM NaF
(pH 7.5), for 30 min at 4 °C. The cell lysates were centrifuged to
remove insoluble materials. For Western blot analysis, whole cell
lysates (20 µg protein/lane) were denatured by boiling in Laemmli
sample buffer containing 100 mM dithiothreitol and resolved
by SDS-PAGE. Gels were transferred to nitrocellulose by electroblotting
in Towbin buffer containing 20% methanol. For immunoblotting,
membranes were blocked and probed with specified antibodies. Blots were
then incubated with horseradish peroxidase-linked second antibody
followed by chemiluminescence detection according to the
manufacturer's instructions (Pierce).
In Vitro Kinase Assay--
Kinase activity was measured by a
solid-phase kinase assay as described previously with some modification
(21). 3T3-L1 adipocytes were infected as described above, starved for
16 h in DME regular glucose medium with 0.05% FCS, stimulated
with 100 ng/ml insulin for 10 min at 37 °C, and lysed. The cell
lysates (300-350 µg) were immunoprecipitated with anti-PDK-1
antibody. The immunocomplexes were recovered by centrifugation at
10,000 × g for 10 s and then washed three times
with a buffer containing 20 mM HEPES (pH 7.5), 150 mM NaCl, 10% glycerol, 20 mM NaF, 0.2 mM Na3VO4, and 0.1% Triton X-100
and once with kinase buffer (20 mM HEPES (pH 7.5), 10 mM MgCl2, 0.2 mM vanadate, and 1 mM dithiothreitol). The immunocomplexes were then incubated
with 30 µl of kinase buffer containing 50 µM unlabeled
ATP, 50 µg of myelin basic protein, and 10 µCi of [ 2-Deoxyglucose Transport--
The procedure for glucose
transport was a modification of the methods described by Klip et
al. (22). Differentiated 3T3-L1 adipocytes were infected with
Ad5-PDK-1WT or Ad5-ctrl at 40 m.o.i. as described above and grown
in medium containing heat-inactivated serum (2%) for 72 h. Serum-
and glucose-deprived cells were incubated in minimum Eagle's
medium- Glycogen Synthesis--
Glycogen synthesis was measured as
described previously (23). 3T3-L1 adipocytes were infected with
Ad5-PDK-1WT or Ad5-PDK-1CAAX at 50 m.o.i. for 16 h and grown
in medium containing 2% heat-inactivated serum for 56 h. The
cells were serum-starved for 16 h, and then medium was replaced
with DME medium containing 1% bovine serum albumin. The cells
were incubated with [14C]glucose (0.4 µCi/well) and 100 ng/ml insulin for 2 h in CO2 incubator, washed with
PBS three times, and lysed with 2 N NaOH at 55 °C.
Synthesized [14C]glycogen was precipitated with cold
glycogen in 66% ethanol and washed, and radioactivity was measured.
Statistics--
The values are expressed as mean ± S.E.
unless otherwise stated. The step-down method by Tukey-Welsch was used
to determine the significance of any differences among more than four
groups. p < 0.05 was considered significant.
Effect of Co-expression of PDK-1 on Akt Phosphorylation in Sf-9
Cells--
Recombinant His-tagged Akt-1 baculovirus was infected to
Sf-9 cells with or without the following infection of baculovirus including His-3-phosphoinositide-dependent protein kinase-1
(PDK-1) at the indicated multiplicity of infection. As shown in
Fig. 1, overexpressed PDK-1 was
autophosphorylated and phosphorylated Akt. Thus, our PDK-1
has kinase activity to phosphorylate Akt.
Expression of PDK-1WT and PDK-1CAAX in Rat Primary Cultured
Hepatocytes or 3T3-L1 Adipocytes--
Isolated primary cultured
hepatocytes were infected with recombinant adenovirus expressing wild
type PDK-1, Ad5-PDK-1WT, or membrane-targeted PDK-1, Ad5-PDK-1CAAX, at
10 m.o.i. for 1 h. Following a 24-h incubation, the cells
were fixed, permeabilized, and incubated with anti-PDK-1 antibody.
Overexpressed PDK-1WT existed mainly in cytosol, and PDK-1CAAX was
located at the plasma membrane (Fig.
2A).
Differentiated 3T3-L1 adipocytes were infected with Ad5-PDK-1WT
or Ad5-PDK-1CAAX at 40 m.o.i. for 16 h. Following a 56-h
incubation, the cells were starved for 16 h and stimulated with
100 ng/ml insulin for 30 min. The cells were lysed and analyzed by
SDS-PAGE followed by Western blotting with anti-PDK-1 antibody (Fig.
2B). Overexpressed PDK-1WT showed a mobility shift at the
basal condition and shifted more by insulin stimulation. PDK-1CAAX was
highly shifted at the basal condition, and insulin stimulation had no additive effect. Insulin stimulation led to tyrosine phosphorylation of
PDK-1WT, but PDK-1CAAX was already tyrosine-phosphorylated at the basal
condition (Fig. 2C). We were not able to see any phosphorylation bands in control cells, probably because of a small amount of endogenous PDK-1 protein (data not shown).
In Vitro Kinase Activity of Overexpressed PDK-1 in 3T3-L1
Adipocytes--
Cell lysates from 3T3-L1 adipocytes infected with
Ad5-PDK-1WT or Ad5-PDK-1CAAX at 40 m.o.i. were immunoprecipitated
with anti-PDK-1 antibody, and in vitro kinase activity was
measured using MBP as substrate (Fig. 3).
Insulin stimulated PDK-1 activity ~1.3-fold in uninfected 3T3-L1
adipocytes. PDK-1WT overexpression itself increased PDK-1 activity
~6-fold at the basal condition, and insulin had no additive effect.
PDK-1CAAX expression also elevated kinase activity ~2.4-fold at the
basal condition, and insulin had no additive effect but it showed lower
activity than PDK-1WT.
Effects of PDK-1 Expression on Atypical-PKC Phosphorylation in
3T3-L1 Adipocytes--
Differentiated 3T3-L1 adipocytes were infected
with Ad5-PDK-1WT or Ad5-PDK-1CAAX at 40 m.o.i. and stimulated with
100 ng/ml insulin for 10 min. The cells then were lysed, and Western
blotting was performed by anti-phosphospecific PKC Effects of PDK-1 Expression on Akt and GSK-3 Phosphorylation in
3T3-L1 Adipocytes--
PDK-1WT or PDK-1CAAX expressing 3T3-L1
adipocytes were stimulated with or without insulin for 30 min, lysed,
and analyzed by Western blotting with phosphospecific Akt or GSK-3
antibody. In Fig. 4B, PDK-1CAAX expression stimulated Akt
phosphorylation on both Thr308 and
Ser473 at the basal condition weakly but significantly.
This increased phosphorylation of Akt led the phosphorylation of GSK-3
up to the insulin-stimulated level at the basal condition (Fig.
4C). PDK-1WT expression caused small phosphorylation of Akt
and GSK-3 at the basal condition. PDK-1CAAX and PDK-1WT overexpression
caused the phosphorylation of p70S6 kinase at basal level as well as Akt (data not shown).
Effects of PDK-1 Expression on Glycogen Synthesis and
2-Deoxy-glucose Uptake in 3T3-L1 Adipocytes--
We next measured the
effect of PDK-1WT and PDK-1CAAX on glycogen synthesis in 3T3-L1
adipocytes. Surprisingly, PDK-1CAAX inhibited glycogen synthesis >50%
both at the basal and insulin-stimulated conditions (Fig.
5). PDK-1WT also inhibited glycogen
synthesis, but this effect was weaker than PDK-1CAAX. On the
other hand, neither PDK-1WT nor PDK-1CAAX overexpression affected both
Glut4 translocation from cytosol to plasma membrane and glucose uptake both at the basal and insulin-stimulated conditions (Fig.
6, A and B).
Effects of PDK-1 Expression on MAPK Phosphorylation in 3T3-L1
Adipocytes--
PDK-1WT or CAAX expressing 3T3-L1 adipocytes were
stimulated with insulin for 10 min, lysed, and subjected to SDS-PAGE
followed by Western blotting with anti-phosphospecific ERK1/2 antibody (Fig. 7). PDK-1WT expression had no
significant effect on ERK1/2 phosphorylation in 3T3-L1 adipocytes.
Interestingly, PDK-1CAAX expression inhibited the insulin-stimulated
ERK1/2 phosphorylation in a dose-dependent manner.
PDK-1 was originally cloned as Akt kinase, and several lines of
evidence demonstrated that PDK-1 played an important role to mediate
signal transduction in the PI 3-kinase pathway. We cloned a full-length
pdk-1 cDNA from a human brain cDNA library and
overexpressed PDK-1WT or PDK-1CAAX by adenovirus-mediated gene
transfer. Our cloned PDK-1 was autophosphorylated and phosphorylated Akt in Sf-9 cells in the baculovirus system (Fig. 1). Moreover, overexpression of PDK-1WT showed elevated kinase activity in 3T3-L1 adipocytes (Fig. 3). Thus, our cloned PDK-1 appeared to be an intact
enzyme. However, surprisingly, the overexpression of PDK-1WT did not
significantly enhance the phosphorylation of Akt and GSK-3 at the basal
condition (Fig. 4). It was previously suggested that PDK-1 was
constitutively active in cells and that phosphorylation and activation
of its downstream substrates was mediated mainly by translocation and
conformational changes in its substrates (24, 25). Furthermore, PDK-1
purified from cells was constitutively active and treatment of cells
with mitogen did not stimulate PDK-1 activity in vitro (26).
Moreover, the translocation of PDK-1 to the plasma membrane was also
important in allowing PDK-1 to activate Akt (27). However, it was
recently reported that overexpression of the constitutively active
mutant PDK-1Ala280-Val but not wild type PDK-1 was able to
phosphorylate Akt at Thr308 to the same extent as that
stimulated by insulin (16). PDK-1 Ala280-Val localized in
the cytosol and at the plasma membrane, and PDK-1Ala280-Val
lacking the pleckstrin homology domain, which localized predominantly in the cytosol, showed much weaker effect to phosphorylate Akt. In this
study, the overexpression of PDK-1WT showed a high level of kinase
activity at the basal condition (Fig. 3), so it appeared constitutively
active. However, insulin stimulation or co-expression of
membrane-targeted p110 (p110CAAX) (4) caused a mobility shift of
PDK-1WT (data not shown). Furthermore, insulin stimulated tyrosine
phosphorylation of PDK-1WT (Fig. 2). It was reported recently (28) that
phosphorylation of PDK-1 on Tyr373/376 is important for
PDK-1 activity. Thus, this additional phosphorylation by the PI
3-kinase pathway may be important for activation of its downstream
molecules. In fact, overexpressed PDK-1CAAX was mobility-shifted
more, tyrosine-phosphorylated, and able to phosphorylate Akt
and GSK-3 without stimulation more strongly than PDK-1WT (Figs. 2 and
4). On the other hand, the amount of the insulin-stimulated tyrosyl-phosphorylated PDK-1WT was the same as PDK-1CAAX, but insulin-stimulated mobility shift of PDK-1WT was not so great as that
of PDK-1CAAX. Thus, only the phosphorylation of tyrosine residues is
not able to explain mobility shift, and phosphorylation of other
residues may occur by membrane targeting. Further study is still needed
to clarify this mechanism. PDK-1CAAX-expressing cells had higher
activity than control cells at the basal condition, but it was much
lower than that of PDK-1WT (Fig. 3). The expression level of PDK-1WT
and PDK-1CAAX was comparable, but kinase activity per protein was 1, 0.9, and 0.25 in endogenous PDK-1, PDK-1WT, and PDK-1CAAX,
respectively. This means that increased kinase activity in PDK-1WT
cells was the result of increased protein mass, but membrane-targeted
PDK-1 had lower activity. Because we measured kinase activity in
vitro by using MBP as substrate, the attached CAAX signal might
interfere with the affinity between PDK-1 and MBP. Another
possibility is that membrane localization might be affected by negative
regulator for kinase activity of PDK-1. However, at least it
supports the fact that membrane localization is important because
PDK-1CAAX has lower kinase activity than PDK-1WT but stimulates the
phosphorylation of Akt and GSK-3 more strongly at the basal condition.
PDK-1WT showed small effects for its downstream molecules at the basal
condition. It is possible that a part of overexpressing PDK-1WT exists
near the plasma membrane by chance, and it behaves like PDK-1CAAX. On
the other hand, atypical PKC was fully activated by PDK-1WT
overexpression alone at the basal conditions and showed no further
stimulation by insulin (Fig. 4). These data suggest that PDK-1
stimulates Akt, GSK-3, and atypical PKC by different mechanisms.
Localization of PDK-1 is important for activation of Akt and GSK-3 but
not for atypical PKC.
The ability of PDK-1CAAX to phosphorylate Akt at the basal state was
much weaker than insulin stimulation. It is known that Akt translocates
to plasma membrane in a phosphatidylinositol 3,4,5-trisphosphate-dependent manner and gets
phosphorylation by PDK-1. When PDK-1CAAX is overexpressed, PI 3-kinase
is not activated. Thus, it is possible that because Akt does not
translocate to plasma membrane, PDK-1CAAX is not able to interact with
Akt, even though PDK-1CAAX is enough to phosphorylate Akt.
It was reported that the membrane-targeted Akt and the constitutively
active Akt mutant stimulated glucose transport without insulin
stimulation (5). Another study (6) showed that a dominant negative
PKC PDK-1CAAX fully stimulated GSK-3 phosphorylation but inhibited glycogen
synthesis (Figs. 4 and 5). We previously reported that
membrane-targeted PI 3-kinase (p110CAAX) constitutively activated Akt
but inhibited glycogen synthesis (4). Thus, constitutive activation of
Akt-GSK-3 pathway may inhibit glycogen synthesis because of
desensitization. It is possible that activated GSK-3 stimulates
glycogen synthesis, and increased glycogen content may provide a
feedback signal to diminish synthesis rate. To supporting this idea,
PDK-1WT also stimulated Akt-GSK-3 pathway; however, it was weak, so
glycogen synthesis was partially inhibited in the cells expressing
PDK-1WT.
A previous study reported that the expression of a dominant-negative
In summary, wild type PDK-1 overexpression is sufficient for
phosphorylation of atypical PKC, but membrane localization is needed
for Akt and GSK-3 activation. Moreover, the activation of both atypical
PKC and Akt alone is insufficient for glucose transport in 3T3-L1 adipocytes.
/
without insulin stimulation but showed only the minimum effects to
stimulate phosphorylation of Akt and GSK-3. In contrast, the
overexpression of PDK-1CAAX caused phosphorylation of Akt and GSK-3
more strongly without insulin stimulation. However, PDK-1CAAX did not
affect 2-deoxyglucose uptake and inhibited glycogen synthesis,
surprisingly. Finally, PDK-1CAAX expression inhibited insulin-induced
ERK1/2 phosphorylation in a dose-dependent manner. Taken
together, the translocation of PDK-1 from cytosol to the plasma
membrane is critical for Akt and GSK-3 activation. On the other hand,
only atypical PKC and Akt activation was insufficient for stimulation
of glucose transport, and constitutive activation of Akt-GSK-3 pathway
may inhibit glycogen synthesis and MAPK cascade in 3T3-L1 adipocytes.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
p85, which was not able to
bind insulin receptor and insulin receptor substrates, inhibited
both the insulin-stimulated translocation of Glut4 and glucose
transport (1-3). The membrane-targeted p110 subunit of PI 3-kinase,
which is constitutively active, stimulated glucose transport without
insulin stimulation (4). Thus, PI 3-kinase pathway plays an important
role on this effect of insulin.
and PKC
, are
known to be downstream molecules of PI 3-kinase. It was reported that
membrane-targeted Akt activated glucose transport without insulin
stimulation (5). Thus, Akt activation looks sufficient for glucose
transport. On the other hand, another group showed that a dominant
negative PKC
inhibited insulin-stimulated glucose transport without
affecting Akt activity (6). Thus, the molecular mechanism and candidate
signaling molecule(s) for insulin-stimulated glucose transport is/are
still unclear.
(12, 13), and PKC
/
II (14). Thus, PDK-1 mediates signaling pathways between PI 3-kinase and
its downstream molecules, and it is possible that PDK-1 plays an
important role on insulin-stimulated glucose transport. In fact, it was
reported that the overexpression of wild type PDK-1 by the
electroporation method provoked the increases in the activity of
cotransfected hemagglutinin-tagged PKC
and concomitantly enhanced hemagglutinin-tagged Glut4 translocation in rat adipocytes (15). However, very recently, it was reported that the overexpression of only
constitutively active mutant PDK-1Ala280-Val but not wild
type PDK-1 was able to phosphorylate Akt at Thr308 to the
same extent as that stimulated by insulin (16). Furthermore, PDK-1Ala280-Val localized in the cytosol and at the plasma
membrane, and PDK-1 Ala280-Val lacking the pleckstrin
homology domain, which localized predominantly in the cytosol, showed
much weaker effect to phosphorylate Akt. Thus, the roles of PDK-1 on
insulin signal transduction are still unclear.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
, -Akt, and -ERK1/2 antibodies were from
Cell Signaling Technology, Inc. (Beverly, MA). Phosphotyrosine antibody
(PY20) was from Transduction Laboratories (Lexington, KY). Horseradish
peroxidase-linked anti-rabbit and anti-mouse antibodies were from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA). Horseradish
peroxidase-linked anti-sheep antibody was from Chemicon (Temecula, CA).
Anti-PKC
antibody, DME medium, and fetal calf serum (FCS) were
obtained from Invitrogen. All radioisotopes were obtained from
PerkinElmer Life Sciences. Kodak X-Omat AR was obtained from Eastman
Kodak Co. All other reagents and chemicals were purchased from Sigma.
-ZAP II phage
(Stratagene) containing full-length human pdk-1 cDNA, in vitro excision was performed using a helper phage
(ExAssistTM, Stratagene). Finally, full-length cDNA
subcloned into pBluescript was isolated.
-glycerophosphate, 1 mM sodium orthovanadate, 4 µg/ml AEBSF (aminoethyl
benzensulfonyl fluoride), 4 µg/ml aprotinin, 4 µg/ml pepstatin A,
and 4 µg/ml leupeptin at 4 °C for 20 min. The cell lysates
were centrifuged at 15,000 × g for 10 min. The
supernatants were incubated with nickel-nitrilotriacetic acid-agarose
(Qiagen, Tokyo, Japan). The immunoprecipitates were washed three times
with lysis buffer and once with kinase buffer containing 20 mmol/liter
HEPES (pH 7.4), and 10 mmol/liter. The kinase reaction was performed
for 10 min at 30 °C in a kinase buffer containing 20 mM
HEPES (pH 7.4), 10 mM MgCl2, 1 mM
dithiothreitol, 100 µM unlabeled ATP, and 0.2 µCi of
[
-32P]ATP. The reaction was terminated by the addition
of SDS-PAGE sample buffer and then analyzed by 9% SDS-PAGE. The
activity was quantified using a PhosphorImager (Amersham Biosciences).
-32P]ATP at 30 °C for 10 min. The reaction was
terminated by the addition of 15 µl of 3× Laemmli sample buffer and
boiling at 100 °C for 5 min. Phosphorylated proteins were resolved
by 15% SDS-PAGE followed by autoradiography. The relative kinase
activities were quantified by Instant-Imager.
in the absence (basal) or presence of the indicated
concentration of insulin for 1 h at 37 °C. Glucose uptake was
determined in duplicate or triplicate at each point after the addition
of 10 µl of substrate (2-[3H]deoxyglucose or
L-[3H]glucose (0.1 µCi), final
concentration (0.01 mmol/liter)) to provide a concentration at which
cell membrane transport was rate-limiting. The value for
L-glucose was subtracted to correct each sample for the
contributions of diffusion and trapping.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (29K):
[in a new window]
Fig. 1.
Effect of co-expression of PDK-1 on
Akt-phosphorylation in Sf-9 cells. Recombinant His-tagged
Akt-1 baculovirus was infected to Sf-9 cells with or without the
following baculovirus including His-PDK-1 at the indicated
multiplicities of infection. After 60 h of infection, cells were
washed with ice-cold PBS and lysed in a solubilizing buffer. The
supernatants were incubated with nickel-nitrilotriacetic acid-agarose.
The immunoprecipitates were washed, and the kinase reaction was
performed for 10 min at 30 °C. Upper panel shows
autoradiography (32P), and lower panel
shows Coomassie Brilliant Blue stain of the gel (CBB).

View larger version (38K):
[in a new window]
Fig. 2.
Expression of PDK-1 in rat primary cultured
hepatocytes and 3T3-L1 adipocytes. Rat primary cultured
hepatocytes were infected with recombinant adenovirus expressing wild
type PDK-1 (WT) and membrane-targeted PDK-1 CAAX
(CAAX) at 10 m.o.i. for 1 h, and then the cells
were incubated anti-PDK-1 antibody (A). Differentiated
3T3-L1 adipocytes were infected with recombinant adenovirus expressing
wild type PDK-1 and CAAX at 40 m.o.i. for 16 h. Following
56-h incubation, the cells were starved for 16 h and stimulated
with or without 100 ng/ml insulin for 30 min. B, the cells
were lysed and analyzed by SDS-PAGE followed by Western blotting with
anti-PDK-1 antibody. C, the cell lysates were
immunoprecipitated by anti-PDK-1 antibody and immunoblotted by
phosphotyrosine antibody. Each Western blot is a representative of
three independent experiments.

View larger version (22K):
[in a new window]
Fig. 3.
In vitro kinase activity of
overexpressed PDK-1 in 3T3-L1 adipocytes. Differentiated 3T3-L1
adipocytes infected with Ad5-PDK-1WT or CAAX at 40 m.o.i. were
stimulated with or without 100 ng/ml insulin, lysed, and
immunoprecipitated with anti-PDK-1 antibody, and in vitro
kinase activity was measured using MBP as the substrate. The kinase
activity is shown as the mean ± S.E. of three experiments, and
the values are expressed as a percentage of the basal activity (=100%)
observed in unstimulated and uninfected cells. *, the difference from
basal values in the uninfected cells at p < 0.01.
/
antibody. As
shown in Fig. 4A, insulin
stimulated the phosphorylation of PKC
/
, and overexpression of
PDK-1WT or PDK-1CAAX caused its phosphorylation without insulin
stimulation. We observed the identical findings by in vitro
kinase assay using MBP as substrate. When basal activity was adjusted
to 100%, PKC
activity was stimulated up to 132 ± 7.8% by
insulin in control cells and up to 140 ± 6.5% and 145 ± 16.8% by PDK-1WT and PDK-1CAAX expression, respectively. Insulin had
no further effects on PDK-1 activity in these cells.

View larger version (79K):
[in a new window]
Fig. 4.
Effects of PDK-1 expression on atypical-PKC,
Akt, and GSK-3 phosphorylation in 3T3-L1 adipocytes.
Differentiated 3T3-L1 adipocytes were infected with PDK-1WT or CAAX at
40 m.o.i., stimulated with insulin for 10 (A) or 30 min
(B and C). The cells then were lysed, and Western
blot was performed by anti-phosphospecific-PKC
/
(p-PKC
/
) (A), -Akt (Thr308)
(p-AKT(Thr)), -Akt (Ser473)
(p-AKT(Ser)) (B), or -GSK-3
(p-GSK-3) (C) antibody. The membranes were
stripped and reblotted with anti-PKC
, -Akt1, or -GSK-3 antibody.
Each Western blot is a representative of three independent
experiments.

View larger version (21K):
[in a new window]
Fig. 5.
Effect of PDK-1 expression on glycogen
synthesis in 3T3-L1 adipocytes. Differentiated 3T3-L1 adipocytes
infected with Ad5-PDK-1WT or CAAX at 40 m.o.i. were stimulated
with or without insulin at the indicated concentrations for 60 min.
Glucose incorporation into glycogen was measured as described under
"Experimental Procedures." The graph shows the mean ± S.E. of four independent experiments, and the values are expressed
as a percentage of the basal activity (=100%) observed in unstimulated
and uninfected cells. *, the difference from the insulin-stimulated
values of each concentration in the cells with control virus at
p < 0.01.

View larger version (49K):
[in a new window]
Fig. 6.
Effects of PDK-1 expression on Glut4
translocation and 2-deoxy-glucose uptake in 3T3-L1 adipocytes.
Differentiated 3T3-L1 adipocytes infected with Ad5-PDK-1 or CAAX at
40 m.o.i. were stimulated with or without insulin at the indicated
concentrations for 60 min. Each fraction was separated by
ultracentrifugation, and Western blot was performed by anti-Glut4
antibody (A). PM, plasma membrane;
LDM, low density microsome. 2-Deoxy-glucose uptake was
measured as described under "Experimental Procedures"
(B). The graph shows the mean ± S.E. of
five independent experiments.

View larger version (25K):
[in a new window]
Fig. 7.
Effects of PDK-1 expression on MAPK
phosphorylation in 3T3-L1 adipocytes. PDK-1WT or CAAX expressing
3T3-L1 adipocytes were stimulated with insulin for 10 min, lysed, and
subjected to SDS-PAGE followed by Western blotting with
anti-phosphospecific MAPK antibody (upper panel). The
membrane then was stripped and reblotted with anti-Erk1 antibody
(lower panel).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
inhibited the insulin-stimulated glucose transport without
affecting Akt activity. Thus, the molecular mechanism of
insulin-stimulated glucose transport is still unclear. In this study,
the overexpression of PDK-1WT stimulated atypical PKC activity but did
not affect glucose transport (Fig. 6), so it is probable that atypical
PKC activation alone is insufficient for stimulation of glucose
transport. It was recently reported that overexpression of atypical PKC
isotype-specific interacting protein, which specifically interacts with
the atypical PKC isozymes PKC
and PKC
, inhibits insulin
stimulation of glucose uptake partially with complete inhibition of
PKC
activity (29). This finding also suggests that other pathways
exist for insulin-stimulated glucose transport with the exception of
atypical PKC. PDK-1CAAX showed full activation of atypical PKC and
partial activation of Akt but did not stimulate glucose transport. Akt
activation is not so great; thus, it may not be enough for the
stimulation of glucose transport. Another explanation is that both
atypical PKC and Akt activation are still not enough for stimulation of glucose transport.
p85 PI 3-kinase subunit, kinase-inactive PDK-1, and kinase-inactive
PKC
inhibited insulin-induced ERK activation in rat adipocytes (30),
suggesting that PI 3-kinase-PDK-1/atypical PKC pathway is important to
activate MAPK cascade. However, in this study, overexpressed PDK-1WT
did not enhance ERK phosphorylation at both the basal and
insulin-stimulated conditions (Fig. 7), even though it stimulated
PKC
. Moreover PDK-1CAAX inhibited the insulin-stimulated ERK
phosphorylation. Similar to these findings, we also previously reported
that p110CAAX did not stimulate ERK phosphorylation at the basal and
inhibited insulin-stimulated ERK phosphorylation, even though a full
activation of PI 3-kinase cascade (4). Because it is reported that Akt
inhibits Raf activation (31-33), constitutive activation of Akt may
decreased insulin-stimulated ERK phosphorylation in the
PDK-1CAAX-expressing cells. Taken together, the activation of the PI
3-kinase/PDK-1 pathway alone is insufficient for ERK activation, and
constitutive activation of this pathway inhibits insulin-stimulated ERK phosphorylation.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. L. C. Cantley (Harvard University, Boston, MA) for providing PDK-1 adenovirus. We are grateful to Dr. J. M. Olefsky (University of California, La Jolla, CA) for donating 3T3-L1. We also thank Drs. A. Bellacosa (Fox Chase Cancer Research Center, Philadelphia, PA) and T-C. He (The Howard Hughes Medical Institute, Baltimore, MD) for providing His-tagged mouse akt-1 and materials for AdEasy system, respectively.
| |
FOOTNOTES |
|---|
* This work was supported in part by a grant-in-aid from the Ministry of Education, Science, Sports and Culture, Japan (to H. M.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AF017995.
§ To whom correspondence should be addressed. Tel.: 81-77-548-2222; Fax: 81-77-543-3858; E-mail: maegawa@belle.shiga-med.ac.jp.
Published, JBC Papers in Press, July 29, 2002, DOI 10.1074/jbc.M203132200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: Glut4, glucose transporter; PI, phosphatidylinositol; PDK-1, 3-phosphoinositide-dependent protein kinase-1; PKC, protein kinase C; ERK, extracellular signal-regulated kinase; DME medium, Dulbecco's modified Eagle's medium; FCS, fetal calf serum; PBS, phosphate-buffered saline; MAPK, mitogen-activated protein kinase; GSK, glycogen synthase kinase-3; MBP, myelin basic protein; PDK-1WT, wild type PDK-1; PDK-1CAAX, membrane-targeted PDK-1; E1, ubiquitin-activating enzyme.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Haruta, T.,
Morris, A. J.,
Rose, D. W.,
Nelson, J. G.,
Mueckler, M.,
and Olefsky, J. M.
(1995)
J. Biol. Chem.
270,
27991-27994 |
| 2. | Sharma, P. M., Egawa, K., Gastafson, T. A., Martin, J. L., and Olefsky, J. M. (1997) Mol. Cell. Biol. 17, 7386-7397[Abstract] |
| 3. | Kotani, K., Carozzi, A. J., Sakaue, H., Hara, K., Robinson, L. J., Clark, S. F., Yonezawa, K., James, D. E., and Kasuga, M. (1995) Biochem. Biophys. Res. Commun. 209, 343-348[CrossRef][Medline] [Order article via Infotrieve] |
| 4. |
Egawa, K.,
Sharma, P. M.,
Nakashima, N.,
Huang, Y.,
Huver, E.,
Boss, G. R.,
and Olefsky, J. M.
(1999)
J. Biol. Chem.
274,
14306-14314 |
| 5. |
Kohn, A. D.,
Summers, S. A.,
Birnbaum, M. J.,
and Roth, R. A.
(1996)
J. Biol. Chem.
271,
31372-31378 |
| 6. |
Kotani, K.,
Ogawa, W.,
Matsumoto, M.,
Kitamura, T.,
Sakaue, H.,
Hino, Y.,
Miyake, K.,
Sano, W.,
Akimoto, K.,
Ohno, S.,
and Kasuga, M.
(1998)
Mol. Cell. Biol.
18,
6971-6982 |
| 7. | Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R., Reese, C. B., and Cohen, P. (1997) Curr. Biol. 7, 261-269[CrossRef][Medline] [Order article via Infotrieve] |
| 8. |
Stephens, L.,
Anderson, K.,
Stokoe, D.,
Erdjument-Bromage, H.,
Painter, G. F.,
Holmes, A. B.,
Gaffney, P. R. J.,
Reese, C. B.,
McCormick, F.,
Tempst, P.,
Coadwell, J.,
and Hawkins, P. T.
(1998)
Science
279,
710-714 |
| 9. | Alessi, D. R., Kozlowski, M. T., Weng, Q. P., Morrice, N., and Avruch, J. (1998) Curr. Biol. 8, 69-81[CrossRef][Medline] [Order article via Infotrieve] |
| 10. |
Pullen, N.,
Dennis, P. B.,
Andjelkovic, M.,
Dufner, A.,
Kozma, S. C.,
Hemmings, B. A.,
and Thomas, G.
(1998)
Science
279,
707-710 |
| 11. |
Balendran, A.,
Currie, R.,
Armstrong, C. G.,
Avruch, J.,
and Alessi, D. R.
(1999)
J. Biol. Chem.
274,
37400-37406 |
| 12. | Chou, M. M., Hou, W., Johnson, J., Graham, L. K., Lee, M. H., Chen, C. S., Newton, A. C., Schaffhausen, B. S., and Toker, A. (1998) Curr. Biol. 8, 1069-1077[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Dong, L. Q.,
Zhang, R.,
Langlais, P., He, H.,
Clark, M.,
Zhu, L.,
and Liu, F.
(1999)
J. Biol. Chem.
274,
8117-8122 |
| 14. | Dutil, E. M., Toker, A., and Newton, A. C. (1998) Curr. Biol. 8, 1366-1375[CrossRef][Medline] [Order article via Infotrieve] |
| 15. |
Bandyopadhyay, G.,
Standaert, M. L.,
Sajan, M. P.,
Karnitz, L. M.,
Cong, L.,
Quon, M. J.,
and Farese, R. V.
(1999)
Mol. Endocrinol.
13,
1766-1772 |
| 16. |
Wick, M. J.,
Dong, L. Q.,
Riojas, R. A.,
Ramos, F. J.,
and Liu, F.
(2000)
J. Biol. Chem.
275,
40400-40406 |
| 17. |
Obata, T.,
Yaffe, M. B.,
Leparc, G. G.,
Piro, E. T.,
Maegawa, H.,
Kashiwagi, A.,
Kikkawa, R.,
and Cantley, L. C.
(2000)
J. Biol. Chem.
275,
36108-36115 |
| 18. |
He, T-C.,
Zhou, S.,
da Costa, L. T., Yu, J.,
Kinzler, K. W.,
and Vogelstein, B.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
2509-2514 |
| 19. |
Nagai, Y.,
Nishio, Y.,
Nakamura, T.,
Maegawa, H.,
Kikkawa, R.,
and Kashiwagi, A.
(2002)
Am. J. Physiol.
282,
E1180-E1190 |
| 20. |
Nakamura, T.,
Kishi, A.,
Nishio, Y.,
Maegawa, H.,
Egawa, K.,
Norman, C. W. W.,
Kojima, H.,
Fujimiya, M.,
Arai, R.,
Kashiwagi, A.,
and Kikkawa, K.
(2001)
J. Clin. Endocrinol. Metab.
86,
1795-1800 |
| 21. |
Morino, K.,
Maegawa, H.,
Fujita, T.,
Takahara, N.,
Egawa, K.,
Kashiwagi, A.,
and Kikkawa, R.
(2001)
Endocrinology
142,
2669-2676 |
| 22. |
Klip, A., Li, G.,
and Logan, W. J.
(1984)
Am. J. Physiol.
247,
E291-E296 |
| 23. |
Egawa, K.,
Nakashima, N.,
Sharma, P. M.,
Maegawa, H.,
Nagai, Y.,
Kashiwagi, A.,
Kikkawa, R.,
and Olefsky, J. M.
(2000)
Endocrinology
141,
1930-1935 |
| 24. | Belham, C., Wu, S., and Avruch, J. (1999) Curr. Biol. 9, R93-R96[CrossRef][Medline] [Order article via Infotrieve] |
| 25. | Peterson, R. T., and Schreiber, S. L. (1999) Curr. Biol. 9, R521-R524[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Alessi, D. R., Deak, M., Casamayor, A., Caudwell, F. B., Morrice, N., Norman, D. G., Gaffney, P., Reese, C. B., MacDougall, C. N., Harbison, D., Ashworth, A., and Bownes, M. (1997) Curr. Biol. 7, 776-789[CrossRef][Medline] [Order article via Infotrieve] |
| 27. | Anderson, K. E., Coadwell, J., Stephens, L. R., and Hawkins, P. T. (1998) Curr. Biol. 8, 684-691[CrossRef][Medline] [Order article via Infotrieve] |
| 28. |
Park, J.,
Hill, M. M.,
Hess, D.,
Brazil, D. P.,
Hofsteenge, J.,
and Hemming, B. A.
(2001)
J. Biol. Chem.
276,
37459-37471 |
| 29. |
Kotani, K.,
Ogawa, W.,
Hashiramoto, M.,
Onishi, T.,
Ohno, S.,
and Kasuga, M.
(2000)
J. Biol. Chem.
275,
26390-26395 |
| 30. |
Sajan, M.,
Standaert, M. L.,
Bandyopadhyay, G.,
Quon, M. J.,
Burke, T. R., Jr.,
and Farese, R. V.
(1999)
J. Biol. Chem.
274,
30495-30500 |
| 31. |
Rommel, C.,
Clarke, B. A.,
Zimmermann, S.,
Nunez, L.,
Rossman, R.,
Reid, K.,
Moelling, K.,
Yancopoulos, G. D.,
and Glass, D. J.
(1999)
Science
286,
1738-1741 |
| 32. |
Zimmermann, S.,
and Moelling, K.
(1999)
Science
286,
1741-1744 |
| 33. |
Guan, K-L.,
Figueroa, C.,
Brtva, T. R.,
Zhu, T.,
Taylor, J.,
Barbar, T. D.,
and Vojtek, A. B.
(2000)
J. Biol. Chem.
275,
27354-27359 |
This article has been cited by other articles:
![]() |
T. Yoshizaki, T. Imamura, J. L. Babendure, J.-C. Lu, N. Sonoda, and J. M. Olefsky Myosin 5a Is an Insulin-Stimulated Akt2 (Protein Kinase B{beta}) Substrate Modulating GLUT4 Vesicle Translocation Mol. Cell. Biol., July 15, 2007; 27(14): 5172 - 5183. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Primo, L. di Blasio, C. Roca, S. Droetto, R. Piva, B. Schaffhausen, and F. Bussolino Essential role of PDK1 in regulating endothelial cell migration J. Cell Biol., March 26, 2007; 176(7): 1035 - 1047. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Tao, H. Maegawa, S. Ugi, K. Ikeda, Y. Nagai, K. Egawa, T. Nakamura, S. Tsukada, Y. Nishio, S. Maeda, et al. The Transcription Factor AP-2{beta} Causes Cell Enlargement and Insulin Resistance in 3T3-L1 Adipocytes Endocrinology, April 1, 2006; 147(4): 1685 - 1696. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. V. Farese, M. P. Sajan, and M. L. Standaert Insulin-Sensitive Protein Kinases (Atypical Protein Kinase C and Protein Kinase B/Akt): Actions and Defects in Obesity and Type II Diabetes Experimental Biology and Medicine, October 1, 2005; 230(9): 593 - 605. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ugi, T. Imamura, H. Maegawa, K. Egawa, T. Yoshizaki, K. Shi, T. Obata, Y. Ebina, A. Kashiwagi, and J. M. Olefsky Protein Phosphatase 2A Negatively Regulates Insulin's Metabolic Signaling Pathway by Inhibiting Akt (Protein Kinase B) Activity in 3T3-L1 Adipocytes Mol. Cell. Biol., October 1, 2004; 24(19): 8778 - 8789. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. King and A. C. Newton The Adaptor Protein Grb14 Regulates the Localization of 3-Phosphoinositide-dependent Kinase-1 J. Biol. Chem., September 3, 2004; 279(36): 37518 - 37527. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Halayko, S. Kartha, G. L. Stelmack, J. McConville, J. Tam, B. Camoretti-Mercado, S. M. Forsythe, M. B. Hershenson, and J. Solway Phophatidylinositol-3 Kinase/Mammalian Target of Rapamycin/p70S6K Regulates Contractile Protein Accumulation in Airway Myocyte Differentiation Am. J. Respir. Cell Mol. Biol., September 1, 2004; 31(3): 266 - 275. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Shi, K. Egawa, H. Maegawa, T. Nakamura, S. Ugi, Y. Nishio, and A. Kashiwagi Protein-Tyrosine Phosphatase 1B Associates with Insulin Receptor and Negatively Regulates Insulin Signaling without Receptor Internalization J. Biochem., July 1, 2004; 136(1): 89 - 96. [Abstract] [Full Text] [PDF] |
||||
![]() |
|